FFM
TARA icon

Fairmount Funds Management’s Protara Therapeutics TARA Stock Holding History

Fairmount Funds Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,544
Closed -$140K – 16
2019
Q4 		$140K Buy
+8,544
New +$98K 0.08% 15

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Fairmount Funds Management's TARA Position: Q1 2020 in Review

Fairmount Funds Management sold out of Protara Therapeutics (TARA) in Q1 2020, closing a stake of 8,544 shares — an estimated $140K sold.

Fairmount Funds Management first reported a position in TARA in Q4 2019 and held it in 1 quarter. The position peaked at $140K in Q4 2019. 28 funds tracked by Wall St. Rank hold TARA as of Q1 2020.

  • Fairmount Funds Management reported no remaining Protara Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Fairmount Funds Management sold 8,544 Protara Therapeutics shares in Q1 2020, an estimated $140K.
  • Fairmount Funds Management first reported a position in Protara Therapeutics in Q4 2019 and held it in 1 quarter.
  • Fairmount Funds Management's Protara Therapeutics position peaked at $140K in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2020.

Based on Fairmount Funds Management's 13F filing for Q1 2020, filed 8 May 2020.